At long last, what if a drug could help us live longer, healthier lives? UT Health Science Center Barshop Institute researchers are moving the science of healthy aging from the idea stage to clinical trials in an effort to prove that aging interventions, such as Rapamycin, actually work in humans.
TPR’s inaugural Think Health Science Event, A Leap Toward a Treatment for Alzheimer’s Disease, focuses on the latest research and discoveries related to the treatment of Alzheimer’s Disease. Our speaker is Veronica Galvan, Ph.D., Researcher of the Barshop Institute at the University of Texas Health Science Center at San Antonio.
View slides and listen to the audio of the full presentation below. TPR's Shelley Kofler is emcee and moderator.
Veronica Galvan, Ph.D., studies the biology of Alzheimer’s disease at the Barshop Institute for Longevity and Aging Studies, one of the world’s most renowned aging research institutes. The Barshop Institute is a key research component of The University of Texas Health Science Center at San Antonio. Dr. Galvan grew up in Buenos Aires, Argentina, where she earned her molecular biology degree at the Center for Advanced Studies in Exact Sciences. She subsequently earned her doctoral degree at the University of Chicago. After a postdoctoral fellowship in neurobiology at the Buck Institute in Northern California, Dr. Galvan joined the Barshop Institute in 2009. She is an assistant professor in the Department of Physiology at the UT Health Science Center. Her laboratory has discovered that a drug that delays aging, rapamycin, reverses Alzheimer’s-like memory deficits and has other desirable effects in the brains of mice that model the disease. This is the first time that the progression of Alzheimer’s-like disease or any other dementia modeled in mice has been blocked by a drug that slows aging. She is married to Matthew Hart, Ph.D., assistant professor of biochemistry at the Health Science Center.
Think Health Science is made possible in part by UT Medicine-San Antonio.